ISSN 1016-5169 | E-ISSN 1308-4488
Archives of the Turkish Society of Cardiology
Doxorubicin-Induced Experimental Cardiotoxicity and Effect of Pentoxphylline on Cardiotoxicity [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 2004; 32(5): 279-287

Doxorubicin-Induced Experimental Cardiotoxicity and Effect of Pentoxphylline on Cardiotoxicity

Figen NARİN1, Ferunda DEMİR2, Hülya AKGÜN3, Ali BAYKAN2, Kazım ÜZÜM2, Sibel KUZUGÜDEN1, Esat KÖKLÜ2

Doxorubicin, a widely used antineoplastic agent in clinical practice, has a serious side effect, as cardiotoxicity. Due to the risk of life-threatening cardiotoxicity which limits doxorubicin's therapeutic potential, diagnosis and prevention of doxorubicin-induced cardiotoxicity becomes essential. Free radicals, lipid peroxidation and antioxidant enzymes are suggested to be involved mainly in doxorubicin-induced cardiotoxicity pathogenesis. Aim of this study was the investigation of pathogenesis of doxorubicine induced cardiotoxicity and the effect of the pentoxphylline on this subject. The study was designed on three groups: the first group (n=10 young rabbit) who took 6 daily doses of intraperitoneal doxorubicine (cumulative dose 15mg/kg) for 15 days. The second group (n=10 young rabbit) who received pentoxifylline (40 mg/kg/day intraperitoneal) 24 hours before intraperitoneal doxorubicine and continued 7 days after the last dose of doxorubicine. The third group was a control group (n=7). We measured myocardial and plasma glutathione peroxidase (GSH-Px), superoxide dismutase (SOD), and malondialdehyte (MDA) activities and myocardial nitric oxide (NO) activity in our rabbit model. Serum troponin I (Tn I) and creatine kinase MB (CKMB) values were tested for the assessment of cardiotoxicity. Our results suggested that doxorubicin formed severe cardiotoxicity in young rabbits with 15 mg/kg cumulative doses with markedly decreased myocardial GSH-Px (2.4 mU/µg) and increased MDA (0.056nmol/µg) and NO (0.13 µmol-3/µg) values. Pentoxphylline reduced doxorubicin-induced cardiotoxicity by increasing myocardial GSH-Px (5.6 mU/µg), SOD (5.56 U/µg) activities and decreasing myocardial NO (0.08 µmol-3/µg) activities. Although serum Tn I (2.4 ngr/mL in the first group) and CKMB (4123 U/mL in the first group) levels had diagnostic values, any change in plasma GSH-Px, SOD and MDA activities was determined in assessing doxorubicin-induced cardiotoxicity. In conclusion, decreased antioxidant enzyme levels, increased free radicals and lipid peroxidation play major role in the pathogenesis of doxorubicin-induced cardiotoxicity and pentoxphylline is an effective antioxidant in reducing doxorubicin-induced cardiotoxicity. (Türk Kardiyol Dern Arş 2004; 32: 279-287)

Keywords: Doxorubicin, cardiotoxicity, nitric oxide, glutathione peroxidase, superoxide dismutase, malondialdehyte, pentoxphylline

How to cite this article
Figen NARİN, Ferunda DEMİR, Hülya AKGÜN, Ali BAYKAN, Kazım ÜZÜM, Sibel KUZUGÜDEN, Esat KÖKLÜ. Doxorubicin-Induced Experimental Cardiotoxicity and Effect of Pentoxphylline on Cardiotoxicity. Turk Kardiyol Dern Ars. 2004; 32(5): 279-287
Manuscript Language: Turkish

Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
SCImago Journal Rank: 0.348

Quick Search

Copyright © 2024 Archives of the Turkish Society of Cardiology

Kare Publishing is a subsidiary of Kare Media.